Concentration-dependent effects of transforming growth factor β1 on corneal wound healing by Wang, Lingyan et al.
Concentration-dependent effects of transforming growth factor
β1 on corneal wound healing
Lingyan Wang, Chun-Ying Ko, Erin E. Meyers, Benjamin S. Pedroja, Nadia Pelaez, Audrey M. Bernstein
Mount Sinai School of Medicine, Dept of Ophthalmology, New York, NY
Purpose: There is an unmet challenge to promote wound healing in non-healing wounds such as in the post-LASIK (laser-
assisted in situ keratomileusis) cornea. Using human corneal fibroblasts (HCFs) in cell culture, we investigated the
concentration dependence of the growth factor transforming growth factor β1 (TGFβ1) on wound closure. Although high
concentrations of TGFβ1 leads to scarring, we asked whether low concentrations of TGFβ1 could promote wound healing
without generating a large fibrotic response.
Methods: HCFs were cultured in supplemented serum-free media (SSFM). Cell migration was assessed by scratch-
wounding. SMAD 2/3 and p38 mitogen-activated protein kinase (p38MAPK) localization and α-smooth muscle actin
(α-SMA) organization were evaluated by immunocytochemistry. Active TGFβ was quantified using a luciferase bio-assay.
Results: We found that neutralizing antibody to TGFβ1 reduced cell migration by 73%, compared to immunoglobulin G
(IgG) control, establishing that endogenous TGFβ1 (determined to be 0.01 ng/ml) is necessary to promote cell migration.
To evaluate the concentration-dependent effects of TGFβ1 on wound closure, HCF migration was quantified to determine
the impact of increasing concentrations of TGFβ1 (0.01–1.0 ng/ml). Compared to control (cells in SSFM), the higher
concentrations (0.1 and 1.0 ng/ml TGFβ1) significantly decreased cell migration (63%–86%), induced myofibroblast
differentiation (83%–88%), increased SMAD 2/3 localization into the nucleus (72%–79%) and inhibited the activation
of p38MAPK (51%–63%). In contrast, addition of the lower concentration of TGFβ1 (0.01 ng/ml TGFβ1) promoted a
cell migration rate that was similar to endogenous TGFβ, reduced SMAD 2/3 nuclear localization, and stimulated
p38MAPK activation. A TGFβ1 blocking antibody and the p38MAPK inhibitor, SB202192, was used to demonstrate that
p38MAPK activation is necessary for TGFβ1-induced cell migration.
Conclusions: Together, our data demonstrate that low concentrations of TGFβ1 promote p38MAPK activation that is a
key to HCF migration, suggesting that a low concentration of TGFβ may be useful in treating non-healing corneal wounds.
The identification of signaling pathways that promote
fibroblast migration into a corneal wound to promote healing
without a fibrotic response is an essential area for study. In a
normal  wound  healing  response,  resident  keratocytes  are
activated to become fibroblasts and myofibroblasts. Activated
resident  corneal  fibroblasts  and  bone  marrow  derived
fibrocytes migrate into the wound site [1]. The fibroblast-
secreted  proteases  remodel  damaged  extracellular  matrix
(ECM) and secrete new ECM that acts as “glue” sealing the
wound [2,3].
After laser-assisted in situ keratomileusis (LASIK), the
central flap region is not repopulated with stromal cells and
the cornea remains unhealed [4,5]. This results in a dramatic
decrease in corneal tensile strength [6,7]. Weakening of the
cornea  after  LASIK  has  been  linked  to  corneal  ectasia
whereby  the  post-LASIK  cornea  exhibits  collagen  fibril
thinning and decreased interfibril distance [8]. Furthermore,
because  the  central  cornea  remains  acellular,  there  is  an
increased risk for corneal edema [4,5]. Although these defects
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occur  in  a  small  percentage  of  LASIK  patients,  they  are
potentially severe complications that can lead to loss of vision
and may become a greater public health issue with the aging
of the population who have LASIK corneas.
To advance our understanding of the role of transforming
growth  factor  β  (TGFβ)  in  wound  healing,  we  have
investigated the concentration dependence of TGFβ to wound
closure  in  vitro.  A  dual  role  in  wound  healing  has  been
proposed for TGFβ: It promotes fibroblast cell proliferation
and cell migration necessary to repopulate wounded tissue,
however it also generates adherent myofibroblasts, which aid
in wound closure by contracting wounded tissue but their
persistence in a healing wound leads to scarring. Thus, anti-
TGFβ antibodies that neutralize TGFβ, significantly reduce
myofibroblast differentiation and scarring [9], however, they
also inhibit cell repopulation [10,11]. These data suggest that
TGFβ promotes wound healing and that TGFβ’s divergent
actions may be concentration dependent.
In  corneal  stromal  epithelial  and  endothelial  cells,
activation  of  the  p38  mitogen-activated  protein  kinase
(p38MAPK) pathway after wounding is key to increased cell
migration that is necessary for wound closure [11-13]. In an
effort to identify conditions that promote regenerative healing
in  the  corneal  stroma,  we  investigated  the  relationship
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2835between TGFβ1 concentration and human corneal fibroblast
(HCF) cell migration, wound closure, activation of p38MAPK
and SMAD 2/3 pathways in vitro. After evaluating a range of
concentrations, we determined that addition of 0.01 ng/ml
TGFβ  most  closely  resembled  the  activity  of  endogenous
TGFβ  for  promoting  cell  migration,  wound  closure,  and
p38MAPK  activation  without  generating  a  large  fibrotic
response.
METHODS
Antibodies and reagents: Transformed mink lung epithelial
cells  (TMLC)  containing  the  plasminogen  activators
inhibitor-1 (PAI-1) promoter fused to the luciferase gene were
a generous gift of Dr. Daniel Rifkin, New York University,
New York, NY. SMAD 2/3 antibody was from Santa Cruz
Biotechnology  (sc-133098;  Santa  Cruz,  CA),  α-smooth
muscle actin (α-SMA) antibody was from Sigma (clone 1A4;
St. Louis, MO). P38MAPK antibody (ab31828) and Phosph-
p38MAPK  antibody  (ab32557)  and  TGFβ1  antibody
(ab10517) was from Abcam (Cambridge, MA). Secondary
Alexa-488 was from Jackson ImmunoResearch (West Grove,
PA). Immunoglobulin G (IgG) Antibody was from Jackson
ImmunoReserach.  TGFβRI  inhibitor,  SB431542  and
p38MAPK inhibitor, SB202190, was from Tocris Bioscience
(Ellisville,  MO).  Bovine  collagen  (PureCol)  was  from
Advanced  Biomatrix  (San  Diego,  CA).  TGFβ1  was  from
R&D Systems (Minneapolis, MN).
Preparation of human corneal cells: HCF were derived from
the  stroma  of  human  corneas  that  were  not  suitable  for
transplantation  (obtained  from  National  Disease  Research
Interchange  (NDRI),  Pittsburgh,  PA).  Stromal  keratocytes
were  isolated  as  previously  described  [14].  To  produce
fibroblasts, freshly isolated corneal stromal keratocytes were
cultured in DMEM-F12 with antibiotic antimycotic (ABAM)
and gentamicin (all from Sigma) plus 10% fetal bovine serum
(FBS,  Atlanta  Biological,  Lawrenceville,  GA).  All
experiments  were  done  on  10  μg/ml  bovine  collagen  I
(Advanced  Biomatrix)  in  supplemented  serum-free  media
(SSFM: DMEM/F-12, 1X RPMI-1640 Vitamin Mix, 1× ITS
Liquid media supplement (5 μg/ml each of insulin, transferrin,
and 0.05 μg/ml sodium selenite), 1 μg/ml glutathione; (all
from Sigma), 1 mM sodium pyruvate, 0.1 mM MEM non-
essential amino acids; (all from Gibco-BRL) with ABAM
(antibiotic antimycotic, Sigma) and gentamicin (Invitrogen,
Carlsbad, CA).
Migration assay: HCFs were seeded at confluency (1×105
cells/well)  on  10  μg/ml  collagen  in  SSFM.  The  next  day
cultures were scraped wounded with a 200 μl pipette tip,
medium was replaced. After an incubation at 37 °C for 24 h,
migration was assessed with T-Scratch software developed by
Koumoutsakos  group  (CSE  laboratory),  at  ETH,  Zürich,
Switzerland. Briefly, images taken at 24 h for each treatment
are imported into this application. This software determines a
percent wound closure (the space remaining in the scratch
wound) compared to the control (time zero after wounding).
For inhibition studies we added 2.5 μg/ml TGFβ1 antibody,
2.5 μg/ml matched IgG control, 10 μM SB202192, or 10 μM
SB431542.
Immunocytochemistry:  Cells  were  fixed  with  3%  p-
formaldehyde (Fisher Scientific, Fair Lawn, NJ) in PBS for
15 min at RT and permeabilized with 0.1% Triton X-100 for
1 min at RT. After blocking non-specific binding with 3%
normal mouse serum (Jackson ImmunoResearch), cells were
incubated  with  anti-α-SMA  antibody  or  anti-SMAD  2/3
antibody or anti-p38MAPK antibody followed by Alexa-488
secondary. After washing, coverslips were mounted on slides
for viewing with a Zeiss Axioskop microscope and images
were captured using a Zeiss Axioscope with a SPOT-2 CCD
camera (Diagnostic Instruments, Sterling Heights, MI) and
processed  by  Adobe  Photoshop  (Adobe,  San  Jose,  CA)
software.  Photoshop  images  were  exported  into  the
MetaMorph image analysis software package (version 6.3r3;
Molecular Devices, Sunnyvale, CA) to determine relative cell
area.
TGFβ  activity  assay:  This  bioassay  detects  active  TGFβ.
HCFs were co-cultured with TMLC containing the PAI-1
promoter fused to the luciferase gene. Extracellular TGFβ
binds to its receptors and signals intracellularly to activate the
PAI-1 promoter. HCFs and TMLC were plated together, each
at 1×105 cells per well in 24 well dishes in DMEM, 10% FBS,
1 mM L-glutamine with antibiotics. After 24 h the media were
replaced with (0.1% BSA in DMEM) and further incubated
for 24 h. Luciferase activity was measured using the Bright-
Glo  detection  system  (Promega,  Madison,  WI)  and
luminescence was determined using a Synergy 2 multi-mode
Microplate  Reader  (Biotek,  Winooski,  VT).  Addition  of
known  amounts  of  recombinant  human  TGFβ1  (R&D
Systems) to TMLC cells was used to generate the standard
curve.
BrdU staining (data not shown): Proliferation assays were
attempted using two methods. First, HCFs were seeded at low
density on collagen in 100 mm plate in either SSFM alone or
with increasing concentrations of TGFβ (0.01, 0.1, or 1.0 ng/
ml  TGFβ).  After  24  h  10  μM  BrdU  (Cell  Signaling
Technology, Beverly, MA) was added for 4 h before fixation
with methanol at −20 °C for 10 min. DNA was then denatured
in 2 M HCL for 1 h and integrated BrdU was detected by anti-
BrdU  monoclonal  antibody  (Cell  Signaling  Technology)
followed by FITC-conjugated goat anti- mouse secondary
antibody (Jackson ImmunoResearch) for 30 min and counter
stained  by  propidium  iodide.  Slides  were  evaluated  using
Zeiss Axioscope with a SPOT-2 CCD camera (Diagnostic
Instruments). In the second method, HCFs were seeded at
confluency on collagen in a 100 mm plate in SSFM. After 24
h, cells were scratch wounded (using a grid to ensure an equal
number of scratches per plate) in the presence of either SSFM
or SSFM with increasing TGFβ concentrations (as above)
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BrdU  as  above.  Differences  between  conditions  were  not
observed using either technique.
Activation of p38MAPK by western blot: HCFs were seeded
at confluence 2×106 on collagen in SSFM. The next day cells
were  scratch  wounded  using  a  grid  to  produce  consistent
wounding per plate. Media was exchanged and reagents were
added. After 4 h, cells were lysed in RIPA buffer (50 mM Tris,
pH  7.4,  150  mM  NaCl,  0.1%  SDS,  0.5%  sodium
deoxycholate,  1%  Triton)  with  protease  inhibitors  (Roche
Applied  Scientific,  Indianapolis,  IN)  and  the  phosphatase
inhibitors (HALT; Thermo Scientific , Rockford, IL tific).
Lysates  were  western  blotted  for  p38MAPK  and  phosph-
p38MAPK. Ratios of P-p38MAPK/p38MAPK are graphed.
Statistical analysis: Standard error between experiments was
calculated. All experiments were repeated at least 3 times. P-
values  were  calculated  using  the  students  t-test.  *p-value
<0.05, **p-value <0.01, ***p-value <0.001.
RESULTS
Neutralizing  TGFβ  activity  inhibits  cell  migration:
Endogenous TGFβ is increased in cells at the wound edge of
wounded corneal fibroblasts in vitro [15]. To confirm that
endogenous  TGFβ  is  necessary  for  HCF  migration,  after
scratch-wounding of confluent cells, we blocked TGFβ by
adding  neutralizing  TGFβ1  antibody  or  matched  IgG
(control). Neutralizing antibody inhibits total TGFβ1 activity
since  it  binds  latency-associated  peptide  (LAP)-TGFβ
preventing the generation of new TGFβ1 as well as binding
active TGFβ [16]. A caveat to this experiment is that LAP may
contribute to cell migration (unrelated to activation of TGFβ)
[17], however, this has not been demonstrated in HCFs.
HCF migration was visualized by comparing time zero
after wounding (Figure 1A) to 24 h post-wounding (Figure
1B-D). To eliminate the contribution of serum components to
cell migration, all studies were performed on HCFs grown
under  supplemented-serum  free  conditions  (SSFM,  see
methods) on collagen. These data show that under SSFM
conditions, at 24 h, HCFs have almost completely repopulated
the wound area (86%; Figure 1B) whereas, the anti-TGFβ1
antibody  inhibited  cell  migration  by  73%  (Figure  1C)
compared to the IgG control (Figure 1D). Percent migration
into the wound compared to time zero was quantified using
T-Scratch  software  (see  methods;  Figure  1E).  Because
TGFβ  neutralizing  antibody  inhibited  cell  migration,  we
sought to determine the levels of active TGFβ in HCFs when
plated  in  SSFM  using  the  sensitive  TMLC  bioassay  (see
methods). TMLCs contain the PAI-1 (plasminogen activator
inhibitor-1)  promotor  linked  to  the  luciferase  gene  and
TGFβ activates PAI-1 [18]. We have co-cultured TMLC cells
with HCFs to quantify TGFβ activity in HCF in unwounded
cells [19]. Using this assay we determined that HCFs under
SSFM  conditions  have  0.01  ng/ml  active  TGFβ  (either
secreted or localized to their cell surface; Figure 1F). This
assay does not distinguish between TGFβ isoforms however,
TGFβ1  neutralizing  antibody  reduced  active  TGFβ  to
undetectable amounts (data not shown), suggesting that this
is a main isoform.
Increasing TGFβ1 concentration correlates with decreasing
cell migration: HCFs were scratch-wounded under SSFM
conditions (-) and migration rates were compared to HCFs
treated with exogenously added TGFβ1: 0.01 ng/ml, 0.1 ng/
ml, and 1 ng/ml (Figure 2A-E). Percent cell migration was
determined  using  T-Scratch  software  (Figure  2F)  and
summarized  in  Table  1.  All  TGFβ1concentrations  tested
decreased cell migration rates compared to the endogenous
TGFβ1 in SSFM, however differences between SSFM and
addition of 0.01 ng/ml were slight and were not statistically
significant. The affect of TGFβ1 on cell proliferation was also
tested using BrdU staining. However, after 24 h in culture, no
difference in cell proliferation was found (data not shown).
Increasing TGFβ1 concentration generates fibrotic markers:
Since TGFβ is known to promote fibrotic markers, we next
investigated  the  impact  of  TGFβ  concentration  on
myofibroblast  differentiation  as  characterized  by  α-SMA
stress fiber organization and increased cell area. HCFs were
treated with increasing concentrations of TGFβ1 and after 72
h, cells were fixed and immunostained for α-SMA (Figure 3
A-D). As expected, the number of cells with α-SMA stress
fibers increased with TGFβ1 concentration (Figure 3E and
Table 1). Furthermore, using Metamorph analysis software,
we found that increasing TGFβ1 concentrations resulted in a
corresponding increase in their area compared to cells grown
without adding TGFβ1 (Figure 3F). Of note is that 1.0 ng/ml
and 0.1 ng/ml promote similar phenotypic changes in α-SMA
organization and increased cell area suggesting that 0.1 ng/ml
is a threshold concentration for promoting a fibrotic response.
Addition of 0.01 ng/ml TGFβ1 also generated myofibroblasts
after  3  days  in  culture  but  approximately  60%  fewer
myofibroblasts were visualized after treatment with 0.01 ng/
ml compared to the two higher concentrations. As predicted,
HCFs treated with TGFβ neutralizing antibody had no α-SMA
stress fibers (data not shown).
TGFβ1  concentration  affects  p38MAPK  and  SMAD  2/3
activation: Activation of p38MAPK promotes cell migration
and regenerative wound healing in epithelial and endothelial
corneal cells [11-13]. In contrast, activation of SMAD 2/3 is
correlated  with  fibrotic  wound  healing  [20].
Immunocytochemical detection of nuclear versus cytoplasmic
localization  of  p38MAPK  and  SMAD  2/3  is  an  effective
method to detect their activation only at the leading edge since
their activated forms are localized to the nucleus. Thus, to
determine the affect of TGFβ1 on p38MAPK and SMAD 2/3
activation,  HCFs  were  seeded  at  confluence  and  scratch
wounded in the presence of either SSFM alone, or increasing
concentrations of TGFβ1. Nuclear localization of p38MAPK
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2837and SMAD 2/3 in leading edge cells was analyzed at several
time points, from 1 to 8 h after wounding. At 4 h, changes in
nuclear  localization  of  p38MAPK  and  SMAD  2/3,  in
migrating cells was easily quantified. In both cases, activation
is visualized by translocation to the nucleus. In SSFM (Figure
4A)  and  0.01  ng/ml  TGFβ1  (Figure  4B),  p38MAPK  was
activated as indicated by its translocation to the nucleus in the
leading edge cells (arrows). This is in contrast to 0.1 ng/ml
TGFβ1 (Figure 4C) and 1.0 ng/ml TGFβ1 (Figure 4D) in
which p38MAPK was excluded from nuclei (arrows). Data
from  multiple  images  of  only  leading  edge  cells  were
quantified  for  p38MAPK  nuclear  exclusion  (Figure  4  I).
Importantly,  these  data  show  that  addition  of  0.01  ng/ml
TGFβ1 closely resembles that of the endogenous levels of
TGFβ for the activation of p38MAPK suggesting that it is a
key to promoting cell migration. In contrast the two higher
concentrations inhibited p38MAPK activation. These data are
supported  by  western  blots  for  phospho-p38MAPK  and
p38MAPK after scratch wounding (Panel A, in Appendix 1).
We next analyzed SMAD 2/3 activation. As predicted,
SMAD  2/3  nuclear  localization  increased  with  TGFβ1
concentration (Figure 4E-H, arrows). However a low level of
SMAD 2/3 activation is compatible with cell migration since
the  leading  edge  cells  have  detectable  SMAD  2/3  in  the
nucleus compared to the nuclear exclusion in the cells behind
the leading edge (Figure 4E-G). Quantification of leading
edge cells that have discrete SMAD 2/3 localization to the
nucleus is shown in Figure 4J. Data from Figure 1, Figure 2,
Figure 3, and Figure 4 are summarized in Table 1. Next we
sought to determine if activation of p38MAPK and SMAD
2/3 is necessary for cell migration.
P38MAPK  nuclear  localization  is  necessary  for  cell
migration: To assess the importance of p38MAPK activation
and  SMAD  2/3  to  cell  migration,  HCFs  were  seeded  at
confluence and scratch wounded in the presence of specific
inhibitors  to  p38MAPK  and  SMAD  2/3.  Four  h  after
wounding, cells were fixed and immunostained for p38MAPK
and SMAD 2/3. Other cultures of scratch wounded cells were
incubated with inhibitors for 18 h and imaged the next day for
wound closure.
The  p38MAPK  inhibitor  (SB202190)  prevented
translocation of p38MAPK to the nucleus (Figure 5A) and
Figure 1. Endogenously secreted TGFβ1 promotes wound healing. HCFs were seeded on collagen in SSFM at 1×105 cells/ml in a 24 well
dish. The next day cells were scratch-wounded and imaged (A) time zero, or incubated for 24 h with either (B) SSFM (C) 2 μg/ml anti-
TGFβ1 antibody or (D) 2 μg/ml matched IgG control. Bar=200 μm, *inside lines denoting wounded area. E: Using T-Scratch software, percent
cell migration into the wound margin at 24 h compared to time zero was calculated. Each condition was compared to SSFM, **p-value <0.01.
F: To determine endogenous levels of TGFβ, HCFs were co-cultured with TMLC, which contain the PAI-1 promoter fused to the luciferase
gene. This assay demonstrated that HCFs have 0.01 ng/ml active TGFβ. Experiments were repeated at least three times with similar results.
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2838also inhibited cell migration after scratch wounding (Figure
5K), demonstrating that preventing activation of p38MAPK
inhibits cell migration. Since phosphorylation of SMAD 2/3
by p38MAPK is necessary for full activation, SMAD 2/3
nuclear translocation was also prevented [21,22] (Figure 5F).
DMSO control cultures shown in Figure 5B,G,L, were similar
to  cells  in  SSFM  alone  (Figure  4A,E).  To  determine  if
blocking all TGFβ1 signaling could prevent TGFβ-mediated
activation of p38MAPK, neutralizing antibody to TGFβ1 was
added. We found that TGFβ1 antibody prevented activation
of p38MAPK (Figure 5C) and SMAD 2/3 (Figure 5H), as well
as cell migration (Figure 5M). As expected, cells that were
treated  with  control  IgG  (Figure  5D,I,N)  demonstrated
nuclear immunostaining and wound closure rates similar to
that seen in cells in SSFM alone (Figure 4A,E and Figure 1D).
These  data  are  supported  by  western  blots  for  phospho-
p38MAPK and p38MAPK after scratch wounding (Panel B,
in Appendix 1).
Next,  we  assessed  the  importance  of  SMAD  2/3
activation  to  wound  closure.  The  SB431542  inhibitor  at
10 μM prevents activin receptor-like kinase (ALK 4,5,7) and
TGFβRI signaling (SMAD 2/3 activation) but does not inhibit
p38MAPK  activation  [23].  In  cells  treated  with  10  μM
SB431542, p38MAPK was still localized to the nucleus in the
leading edge cells (Figure 5E), but SMAD 2/3 was excluded
from  the  nucleus  (Figure  5J),  and  cells  migrated  at  rates
similar to controls (DMSO; Figure 5O). Since SMAD 2/3 is
excluded from the nucleus and cells still migrate, supports the
hypothesis that a low level of SMAD 2/3 activation is not
necessary for cell migration. These data are quantified in bar
graphs below the images in Figure 5. Left to right: Exclusion
of  p38MAPK  from  the  nucleus  in  leading  edge  cells,
Figure 2. Increasing TGFβ1 concentrations reduces HCF migration. HCFs were seeded on collagen in SSFM at 1×105 cells/ml in a 24 well
dish. The next day cells were scratch-wounded and incubated for 24 h in (A) SSFM, (B) 0.01 ng/ml TGFβ1, (C) 0.1 ng/ml TGFβ1, (D) 1.0
ng/ml TGFβ1, or (E) imaged at time zero. Bar=200 μm. F: Using T-Scratch software, percent cell migration into the wound margin at 24 h
compared to time zero was calculated. Each condition was compared to SSFM, *p-value <0.05, **p-value <0.01. Experiments were repeated
at least three times with similar results.
TABLE 1. SUMMARY OF WOUND HEALING DATA AFTER TGFβ1 TREATMENT.
  TGFβ1
Data summary - 0.01 ng/ml 0.1 ng/ml 1.0 ng/ml
% Cell migration into the wound 86.6±2.3 68.0±9.0 31.9±5.6 12.6±3.6
% Cells with α-SMA stress fibers 2.2±1.4 36.1±4.4 90.2±8.0 85.3±11.3
Cell area (pixel intensity 1000×) 7.4±0.9 10.5±1.4 17.1±2.2 16.9±1.2
% Leading-edge cells with p38MAPK nuclear exclusion                        11.9±6.7                18.7±9.9                 62.7±13.3                74.8±6.4
% Leading-edge cells with SMAD 2/3 in muclei                                       3.0±3.0                  8.4±8.0                 75.2±18.7               82.3±11.6
HCFs were untreated (-), or treated with 0.01 ng/ml TGFβ1, 0.1 ng/ml TGFβ1, or 1.0 ng/ml TGFβ1. This table summarizes the
data from Figure 2 (% cell migration into the wound), Figure 3 (% cells with α-SMA stress fibers and cell area), Figure 4
(% of cells with p38MAPK detected outside the nuclei in leading  edge cells and  % of  cells with SMAD 2/3  concentrated in
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2839Figure 3. Increasing TGFβ1 concentration promotes fibrotic markers. HCFs were seeded on collagen in SSFM at 1×104 cells/ml on coverslips
in a 24 well dish in (A) SSFM, (B) 0.01 ng/ml TGFβ1, (C) 0.1 ng/ml TGFβ1, or (D) 1.0 ng/ml TGFβ1. After 72 h (A-D) were immunostained
for α-SMA. Bar=50 μm. For each condition, cells containing organized α-SMA stress fibers were counted (E) and using MetaMorph Analysis
the relative cell area was quantified (F). For analysis greater than 100 cells per experiment were analyzed. Each condition was compared to
SSFM, **p-value <0.01, ***p-value <0.001. Experiments were repeated at least three times with similar results.
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2840Figure 4. Increasing TGFβ1 concentrations results in a loss of nuclear p38MAPK. HCFs were seeded on collagen in SSFM at 1×105 cells/ml
in a 24 well dish. The next day cells were scratch-wounded and incubated in (A, E) SSFM, (B, F) 0.01 ng/ml TGFβ1, (C, G) 0.1 ng/ml
TGFβ1, or (D, H) 1.0 ng/ml TGFβ. After 4 h cells were fixed and immunostained for p38MAPK (A-D) or SMAD 2/3 (E-H). Bar=50 μm.
Arrows point to nuclei in which we detected either the nuclear localization or nuclear exclusion of p38MAPK and SMAD 2/3. The percent
of cells in which p38MAPK was excluded from nuclei of the leading edge cells is shown in (I). The percent of cells with SMAD 2/3 concentrated
in nuclei in the leading edge cells is shown in (J). Image J software was used for quantification. Each condition was compared to SSFM. ***p-
value <0.001. Experiments were repeated at least three times with similar results.
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2841Figure 5. Nuclear p38MAPK localization is necessary for HCF migration. HCFs were seeded on collagen in SSFM at 1×105 cells/ml in a 24
well dish. The next day cells were scratch-wounded and incubated in (A, F, K) p38MAPK inhibitor, 10 μM SB202190, (B, G, L) DMSO,
(C, H, M) TGFβ1 antibody, (D, I, N) Control IgG, or (E, J, O) TGFβ RI (ALK5) inhibitor 10 μM SB431542. After 4 h cells were fixed and
immunostained for p38MAPK (A-E) or SMAD 2/3 (F-J). Arrows denote the nuclei of leading edge cells in which p38MAPK and SMAD
2/3 were either localized or excluded (Bar=50 μm) or after 18 h cells were imaged (K-O). Bar=200 μm. DMSO is the control for addition of
SB202190 or SB431542. Quantification of all data are shown in the bar graphs below the images. Left to right: Exclusion of p38MAPK from
the nucleus in leading edge cells, exclusion of SMAD 2/3 from the nucleus in leading edge cells, cell migration into the wound. Nuclear
localization was counted using Image J software. Two non-biased people scored cell migration, 0 (less migration) to 5 (most migration). **p-
value <0.01, ***p-value <0.001. NS=not significant. Experiments were repeated at least three times with similar results.
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cell migration into the wound.
Taken together, the data presented in Figure 4, Figure 5,
and Appendix 1 demonstrate that TGFβ1-mediated activation
of  p38MAPK  is  necessary  for  cell  migration  and  wound
closure  in  vitro.  Furthermore,  that  addition  of  a  low
concentration of TGFβ1 such as 0.01 TGFβ1 (additive to
endogenous TGFβ) promotes p38MAPK activation.
DISCUSSION
Non-healing after LASIK: Although LASIK has restored clear
vision to millions of people, the post-LASIK cornea remains
acellular and unhealed and thus there is a need to promote cell
repopulation into the unhealed cornea [4,5]. It is possible that
the lack of cell repopulation after LASIK is because LASIK
remodeling of the stroma alters the ECM in a way that may
inhibit  cell  migration  from  the  non-wounded  peripheral
cornea into the wounded central cornea. It is also possible that,
since the LASIK cut intersects the epithelium only at the edge
of the flap, pro-migratory cytokines originating in the cut
epithelium may not reach the flap bed. Our in vitro study
shows  that  endogenous  TGFβ  promotes  cell  migration.
However,  the  fact  that  post-LASIK  wounds  do  not  heal,
suggests  that  endogenous  TGFβ  is  not  impacting  wound
closure post-LASIK. Thus, we investigated if adding a low
concentration of TGFβ1 (equal to the levels of endogenous
TGFβ)  may  be  useful  in  promoting  cell  migration.  We
demonstrate that TGFβ1 at a low concentration (0.01 ng/ml)
is similar to endogenous TGFβ for promoting cell migration,
suggesting that in the absence of cell migration (and perhaps
endogenous  TGFβ),  addition  of  this  low  concentration  of
TGFβ could substitute for endogenous TGFβ. A recent study
by Mi et al. [24] aimed at increasing flap adhesion after a
“LASIK-like cut” tested TGFβ1 as well as other cytokines for
their ability to promote corneal wound healing. After a LASIK
cut of bovine corneas, the corneas were excised placed in
organ  culture  and  treated  for  4  weeks  with  a  cytokine:
TNFα,  IL-1,  Fas  ligand,  or  TGFβ1.  Addition  of  these
cytokines resulted in greater flap adherence but the corneas
did not remain transparent. Based on our data, the lowest
concentration of TGFβ1 that Mi et al. [24] tested, 0.1 ng/ml,
would generate a significant myofibroblast response. At this
concentration,  we  report  that  90%  of  all  cells  are
myofibroblasts.  Consistent  with  our  findings,  the  authors
predicted  that  a  lower  concentration  could  be  useful  in
increasing flap adhesion without generating corneal haze.
The impact of TGFβ1 concentration on p38MAPK and SMAD
2/3 signaling: TGFβ binds to the TGFβ Receptors I and II,
serine/threonine kinases that initiate downstream signaling
pathways. Our data support the finding that TGFβ (ligand)
concentration  differentially  affects  p38MAPK  and  SMAD
2/3,  signaling  pathways  downstream  of  TGFβ1.  Previous
studies  have  demonstrated  that  pathway  activation  also
depends on receptor expression, receptor kinase activity, and
expression  of  receptor  binding  partners  [25,26].  We
investigated  the  importance  of  TGFβ  concentration  to
p38MAPK  activation  and  its  effect  on  human  corneal
fibroblast  wound  healing  in  vitro  because  of  reports
demonstrating that p38MAPK activation is necessary for cell
migration  in  other  cell  types  [11-13,27].  Consistent  with
previous studies, we found p38MAPK activation in actively
migrating cells. Our findings however add new insights into
the  TGFβ1-mediated  regulation  of  p38MAPK  since  a
concentration  dependence  of  TGFβ  on  p38MAPK  was
revealed: Whereas low concentrations of TGFβ1, endogenous
and (0.01 ng/ml), induced p38MAPK activation, 0.1 ng/ml
and 1.0 ng/ml TGFβ prevented activation of p38MAPK. The
biphasic  data  for  low  and  high  concentrations  of  TGFβ1
suggests  that  TGFβ  receptor  occupancy  initiates  different
signals that regulate p38MAPK activation. Furthermore, these
data  support  our  hypothesis  that  addition  of  0.01  ng/ml
TGFβ1 could be used to stimulate cell migration in vivo.
SMAD 2/3 activation by TGFβ was also investigated.
SMAD’s translocation to the nucleus is often used as a marker
for  the  presence  of  active  TGFβ  and  thus  served  as  an
important control for visualizing and verifying the effect of
increasing concentrations of active TGFβ1. We found that as
expected  for  a  classic  dose  dependent  result,  increasing
concentrations of TGFβ1 led to greater nuclear concentration
of SMAD 2/3, which correlated with reduced migration by
cells at the wound edge. However, a low level of SMAD 2/3
translocation to the nucleus was visualized even under the
most migratory conditions (SSFM and 0.01 ng/ml TGFβ1),
suggesting that SMAD 2/3 activation may be necessary for
cell migration. However, the finding that cells migrated after
treatment with the SMAD 2/3 inhibitor, SB431542, suggested
that this is not the case. In contrast, others have shown that
TGFβ-mediated inhibition of cell proliferation is dependent
on SMAD 2/3 activation [21]. Thus perhaps, the minimal
SMAD  2/3  translocation  to  the  nucleus  prevents  cell
proliferation as the cells are actively migrating.
Conclusion—Together our data suggest that addition of
a low concentration of TGFβ may be useful for promoting
human corneal fibroblast migration into a non-healing wound,
without generating a large fibrotic response. These in vitro
data lay the groundwork for future in vivo studies that will
assess the effects of low levels of TGFβ on flap adhesion and
corneal clarity.
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2845Appendix 1. p38MAPK activation demonstrated by western blot.
HCFs were seeded at confluence in SSFM on collagen in
100 mm plates. The next day cells were scratch-wounded
(grids  were  used  to  generate  consistent  scratching)  and
reagents were added. After 4 h, cells were lysed with RIPA
buffer with protease and phosphatase inhibitors. Lysates were
western  blotted  with  Phospho-p38MAPK  antibody  or
p38MAPK  antibody.  Relative  Pixel  Intensity  (RPI)  was
calculated for each band. A: No TGFβ (-) or plus TGFβ, 0.01,
0.1, 1.0 ng/ml). SSFM is 100%. Each condition was compared
to SSFM,*p value <0.05. B: Lane 1, p38MAPK Inhibitor
(SB202190); Lane 2, DMSO; Lane 3, TGFβ1 antibody; Lane
4,  Control  IgG;  Lane  5,  TGFβRI  inhibitor  (SB431542).
Control  IgG  is  100%.  p  value<0.05.  Experiments  were
repeated 3 times with similar results. To access the data, click
or  select  the  words  “Appendix  1.”  This  will  initiate  the
download of a compressed (pdf) archive that contains the file.
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